Facebook Tracking Image

National Comprehensive Cancer Network



Educational Events & Programs

Pharmaceutical and Biotech Cancer Training June 2020 Virtual

Free Online Program was held June 29, 2020.


 

OVERVIEW

During this interactive online program, pharmaceutical and biotechnology professionals are given the rare opportunity to view the oncology space, its future and its current operational issues from the provider, advocacy, and payer perspectives. Through this pharmaceutical and biotech training program, participants will improve their working knowledge of key business, policy, coverage, reimbursement, informational, and operational issues in oncology while gathering valuable insights into developing effective strategies for navigating the cancer care ecosystem. Pharmaceutical and biotech professionals will learn from key stakeholders what they view to be the most pressing issues in oncology today and how to apply this knowledge to create mutually-successful working relationships.

Please check back often for additional updates regarding this program. If you have any questions, please contact Elyse Desjardins, Senior Manager, Business Development.


MODERATOR

Clifford Goodman Photo

Clifford Goodman, PhD
Senior Vice President
The Lewin Group

 

 

 

CURRICULUM*

Welcome
Robert W. Carlson, MD
Chief Executive Officer
National Comprehensive Cancer Network

Impact of COVID-19 on Patients with Cancer
F. Marc Stewart, MD
Professor of Medicine; Medical Director
Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
Co-Chair
NCCN Best Practices Committee

Moderator
Clifford Goodman, PhD
Senior Vice President
The Lewin Group

Panel Discussion: Meet the NCCN Guidelines Panel Experts

Robert W. Carlson, MD
Chief Executive Officer
National Comprehensive Cancer Network

Daniel Chung, MD
Director, Center for Cancer Risk Analysis
Massachusetts General Hospital Cancer Center
Member
NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal Panel

Ruth O’Regan, MD
Division Head of Hematology and Oncology, Associate Director for Clinical Research
University of Wisconsin Carbone Cancer Center
NCCN Board of Directors, Vice-Chair
Member
Breast Cancer Panel

John A. Thompson, MD
Medical Director, Phase I Clinical Trials Program
Professor, Division of Oncology
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance
Chair
NCCN Guidelines for Management of Immunotherapy-Related Toxicities Panel

Alan P. Venook, MD, FASCO
The Madden Family Distinguished Professor of Medical Oncology and Translational Research
Shorenstein Associate Director, Program Development
UCSF Helen Diller Family Comprehensive Cancer Center
Vice-Chair
NCCN Guidelines for Colon Cancer and Rectal Cancer Panel

Closing Remarks            
Gary J. Weyhmuller, MBA, SPHR
Executive Vice President, Chief Operating Officer
National Comprehensive Cancer Network

*Agenda topics are subject to change.


INTENDED AUDIENCE

Professionals from advocacy, marketing, medical affairs, clinical research, policy and government affairs, and other business areas will better be able to serve their customers with improved knowledge of real-world oncology issues after completion of this program.


Customize your own NCCN Academy curriculum.

NCCN offers the unique opportunity to customize an NCCN Academy curriculum that best aligns with your organization's particular needs and interests.

Approximately 97 percent of recent NCCN Academy attendees say they would attend an NCCN Academy program again or recommend that colleagues attend.